Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 150 mg every two weeks or 300 mg every four weeks with platinum-containing chemotherapy as first-line treatment of adults with unresectable or metastatic ESCC with tumor PD-L1 expression of at least 1.
LAMPGEN ANALYSIS
Why it matters
The alternate dosing intervals apply to the first-line combination use, which has a different patient population from later-line monotherapy.
What research teams should watch
Check treatment line, PD-L1 result, and compatibility of infusion schedules with the selected platinum regimen.
PRIMARY RECORDS